OnSource Executes Definitive Merger Agreement With Osmotics

OnSource announced that it executed a definitive agreement to merge (the "Merger Agreement") with Osmotics Pharma (OPI). OPI is an emerging specialty pharmaceutical company focused on developing prescription products for the treatment of various dermatological disorders, antibiotic-resistant strains of bacteria and certain cancers. OPI has the exclusive worldwide rights covering technologies developed by the University of California and Brigham Young University (BYU). Applications of these technologies are currently being tested by some of the leading research institutions in the world.

Yahoo News (http://biz.yahoo.com/bw/050412/125318.html?.v=1)